As of September 30, 2026, Silicon Laboratories, Inc. carries a market capitalization of 7.40B, placing it among publicly traded companies globally. Its enterprise value stands at 6.96B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 7.40B |
| Enterprise Value | 6.96B |
Silicon Laboratories, Inc.'s next confirmed earnings release is scheduled for February 3, 2027.
| Earnings Date | 2/3/2027 |
As of September 30, 2026, Silicon Laboratories, Inc. has 33.38M shares outstanding.
| Shares Outstanding | 33.38M |
These figures are as of September 30, 2026. The price-to-sales ratio is 8.15, and the price-to-book ratio stands at 6.57.
| PS Ratio | 8.15 |
| PB Ratio | 6.57 |
| P/TBV Ratio | 10.10 |
| P/FCF Ratio | 1,037.02 |
| P/OCF Ratio | 161.10 |
As of September 30, 2026, Silicon Laboratories, Inc. trades at an EV/EBITDA multiple of 680.03 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.96B versus a market cap of 7.40B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 7.72 |
| EV / EBITDA | 680.03 |
As of September 30, 2026, Silicon Laboratories, Inc. maintains a current ratio of 4.60, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.60 |
| Quick Ratio | 3.30 |
| Interest Coverage | 11.08 |
Over the twelve months ended September 30, 2026, Silicon Laboratories, Inc. posted a negative return on equity (ROE) of -1.85, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.57, reflecting losses generated across the asset base. The company generates approximately 466,729.02 in revenue per employee across its workforce of 1,930.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.23 indicates how many times Silicon Laboratories, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | -1.85 |
| Return on Assets (ROA) | -1.57 |
| Revenue Per Employee | 466,729.02 |
| Employee Count | 1,930.00 |
| Inventory Turnover | 3.23 |
Over the twelve months ended September 30, 2026, Silicon Laboratories, Inc. recorded 8.58M in income tax expense. The company reported a pretax loss of -11.74M and -20.32M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 8.58M |
As of the close on November 16, 2026, Silicon Laboratories, Inc.'s stock has gained approximately 81.84% over the past 52 weeks. The 50-day moving average sits at 221.33, while the 200-day moving average is 215.07.
| 52-Week Price Change | 81.84% |
| 50-Day Moving Average | 221.33 |
| 200-Day Moving Average | 215.07 |
Over the twelve months ended September 30, 2026, Silicon Laboratories, Inc. generated 900.79M in revenue and converted that into -20.32M in net income, yielding earnings per share of -0.61. EBITDA reached 10.23M, while operating income came in at -23.05M.
| Revenue | 900.79M |
| Gross Profit | 552.33M |
| Operating Income | -23.05M |
| Pretax Income | -11.74M |
| Net Income | -20.32M |
| EBITDA | 10.23M |
| EBIT | -23.05M |
| Earnings Per Share (EPS) | -0.61 |
These figures are as of September 30, 2026. Total book value stands at 1.13B, with working capital of 567.11M providing operational flexibility.
| Cash & Cash Equivalents | 439.84M |
| Net Debt | -423.01M |
| Equity (Book Value) | 1.13B |
| Book Value Per Share | 33.71 |
| Working Capital | 567.11M |
Silicon Laboratories, Inc. produced 45.55M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -38.45M in capital expenditures, free cash flow totaled 7.10M - equivalent to 0.21 per share.
| Operating Cash Flow | 45.55M |
| Capital Expenditures | -38.45M |
| Free Cash Flow | 7.10M |
| FCF Per Share | 0.21 |
Over the twelve months ended September 30, 2026, Silicon Laboratories, Inc. posted a gross margin of 61.32, reflecting its pricing power and cost economics. The operating margin of -2.56 and net profit margin of -2.26 provide insight into operational efficiency.
| Gross Margin | 61.32 |
| Operating Margin | -2.56 |
| Pretax Margin | -1.30 |
| Profit Margin | -2.26 |
| EBITDA Margin | 1.14 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 0.10, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.21, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Silicon Laboratories, Inc. shareholders.
| Shareholder Yield | 0.21 |
| FCF Yield | 0.10 |
As of September 30, 2026, Silicon Laboratories, Inc. has an Altman Z-Score of 24.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 24.02 |